Status and phase
Conditions
Treatments
About
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.
Full description
This is a Phase Ib, single center study evaluating safety and feasibility of DC vaccine (autologous monocyte-derived dendritic cells [moDCs] pulsed with personalized peptides [PEP-DC]) given in combination with low dose cyclophosphamide, as SOC therapy in patients with advanced or recurrent metastatic NSCLC.
Patients with advanced or metastatic NSCLC (metastatic, recurrent and/or unresectable) who received standard of care therapy for advanced disease with no signs of progression will be eligible for this protocol. Patients may have received any number of prior treatments without restriction and any prior immunotherapy before enrollment to the study. However, only patients receiving the maintenance/continuation of SOC treatment options mentioned below are permitted to enter the study. Patients will be enrolled in the following two cohorts:
In both cohorts, patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination. Each dose of vaccine (PEP-DC) will be formulated in two syringes of 525 microL each and administered on week 2 day 2 (W2D2) of each cycle, as subcutaneous injections. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
INCLUSION CRITERIA AT SCREENING:
Signed informed consent form
Histologically confirmed diagnosis of the NSCLC
Patients with metastatic, recurrent and/or unresectable NSCLC from stage IIIA (not amenable to radical treatment) to stage IVB provided they have not experienced disease progression on their current standard-of-care therapy at screening, as compared to the tumor assessment at the initiation of standard-of-care therapy as confirmed by Computed tomography/Magnetic Resonance Imaging (CT/MRI).
Patients may have received any number of prior treatments without restriction and any prior immunotherapy before enrollment to the study. However, only patients receiving the maintenance/continuation of standard of care (SOC) treatment options mentioned below are permitted to enter the study.
Patient may receive only the following maintenance/continuation of SOC therapy during study treatment, as indicated in each case.
Top 10 personalized peptides (PEP) for the preparation of PEP-DC vaccine has been determined before screening.
Patients >18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 21 days prior registration:
Willing and able to comply with study procedures
For women of childbearing potential (WOCBP: sexually mature women who have not undergone a hysterectomy, have not been naturally post-menopausal for at least 12 consecutive months or have a serum follicle-stimulating hormone (FSH) < 40 mIU/ml):
For men and their female partners: agreement to follow instructions for method(s) of contraception for the couple from screening until 6 months after last vaccine dose, or last cyclophosphamide
Patient is able to undergo leukapheresis
EXCLUSION CRITERIA AT SCREENING:
Pregnant or breast-feeding women
Other malignancy within 2 years prior study enrollment, except for those treated with surgical intervention as curative intent in remission.
Current, recent (within 4 weeks prior registration), or planned participation in an experimental drug study
Patients who show signs of progression according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 at screening
Planned SOC therapy other than the following:
Known hypersensitivity to any component of the study treatment
Any contraindication for using cyclophosphamide
Treatment with systemic immunosuppressive medications within 4 weeks prior vaccination (more than an equivalent of 10mg prednisone per day). Patient who has to receive steroid treatment as premedication before pemetrexed are eligible.
Administration of a live, attenuated vaccine within 8 weeks before registration
• Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior registration or at any time during the study.
Positive serology defined by the following laboratory results:
Positive test for Human Immunodeficiency Virus (HIV)
Patients with active or chronic hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening).
Patients with active hepatitis C. Patients positive for Hepatitis C Virus (HCV) antibody are eligible only if Polymerase Chain Reaction (PCR) is negative for HCV ribonucleic acid (RNA).
Severe infections within 8 weeks prior registration including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia or signs or symptoms of infection requiring oral or IV antibiotics within 8 weeks prior registration.
• Patients receiving routine antibiotic prophylaxis (e.g., to prevent chronic obstructive pulmonary disease exacerbation or for dental extraction) are eligible.
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Treatment with systemic immunostimulatory agents (including but not limited to interferon (IFN)-alpha, interleukin (IL)-2 for any reason within 4 weeks or five half-lives of the drug, whichever is shorter, prior to registration.
Treatment with systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior registration.
TREATMENT ELIGIBILITY CRITERIA:
Treatment eligibility criteria will be assessed within 14 days before the vaccination period start. Patients are eligible to receive PEP-DC vaccination if they meet all the following criteria:
Key conditions required to initiate vaccination:
Confirmation from the CTE GMP laboratory that at least six doses of PEPDC vaccines have been produced and released, and are available for the patient at the CTE GMP facility.
Patient does not have any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that occurred since enrollment and that give reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results or render the patient at high risk from treatment complications.
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 2 weeks of first vaccine injection:
EXCLUSION CRITERIA FOR VACCINATION:
Primary purpose
Allocation
Interventional model
Masking
16 participants in 2 patient groups
Loading...
Central trial contact
Virginie Zimmer, Study Coordinator; Hasna Bouchaab, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal